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Pall Stress Modulates Brain Natriuretic Peptide
roduction in Pressure Overload Cardiomyopathy
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ristin Muller, RN,† Eddy Van Schuerbeeck, RN,* Jozef Bartunek, MD*
alst and Bonheiden, Belgium
OBJECTIVES We postulated that both diastolic and systolic load modulate B-type natriuretic peptide
(BNP) production in human pressure overload hypertrophy/failure.
BACKGROUND In isolated myocytes, diastolic stretch induces BNP messenger ribonucleic acid expression.
However, the mechanism of the BNP release in human hypertrophy remains controversial.
METHODS In 40 patients with symptomatic aortic stenosis (AS), left ventricular (LV) performance and
systolic and diastolic wall stress were calculated from combined invasive and echocardio-
graphic data. Plasma BNP was determined by the rapid point-of-care bedside analyzer
(Biosite Triage, Biosite Diagnostics Inc., San Diego, California).
RESULTS A significant relationship was observed between plasma BNP and pulmonary capillary wedge
pressure (p  0.001), fractional shortening (p  0.001), and aortic valve area (p  0.006).
Furthermore, a significant correlation was noted between BNP and LV mass index (p 
0.005) as well as between BNP and markers of diastolic load such as LV end-diastolic wall
stress (p  0.011), indexed LV end-diastolic volume (p  0.001), and isovolumic relaxation
time (p  0.02). Preoperative BNP levels were elevated in patients with AS compared with
patients without AS. Plasma BNP was higher in AS patients with impaired versus normal
preload reserve (297  56 pg/ml vs. 168  44 pg/ml; p  0.017) and in AS patients with
clinical deterioration after valve replacement compared with those without (399  82 pg/ml
vs. 124  41 pg/ml; p  0.011).
CONCLUSIONS In patients with AS, BNP appears to be regulated not only by systolic but also by diastolic
load. This supports the hypothesis that myocardial stretch modulates BNP production in
human pressure overload hypertrophy/failure. (J Am Coll Cardiol 2004;44:2349–54)
























arain or B-type natriuretic peptide (BNP), a 32-amino-acid
eptide, is continuously released from the heart in response
o ventricular volume expansion and pressure overload (1,2)
nd acts both as a natriuretic and diuretic peptide (3).
ssessment of plasma BNP is a highly sensitive and
ost-effective method for detecting heart failure; BNP levels
re elevated in patients with left ventricular (LV) dysfunc-
ion (4) proportional to New York Heart Association
unctional class and filling pressures (5) and bear prognostic
nformation (6). In patients admitted with decompensated
ongestive heart failure, treatment-related changes in BNP
evels predict mortality and early readmission (7).
The BNP gene is a fetal gene whose expression is
p-regulated in the failing myocardium (8). However,
echanisms regulating BNP gene expression are not clear
2). Whereas in the isolated papillary muscle (9) or in
nimal models (10) diastolic wall stress modulates BNP
ene expression, earlier human data indicate that in aortic
tenosis (AS) with compensated hypertrophy, systolic load
cts as stimulus for production of natriuretic peptides (11).
his suggests that changes in wall stress might play a role in
he synthesis and secretion of BNP and that changes in
NP could reflect the transition from compensated to
ecompensated heart failure. To test this hypothesis, we
From the *Cardiovascular Center, Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium;
nd the †Cardiovascular Center, Imelda Ziekenhuis, Bonheiden, Belgium.s
Manuscript received May 11, 2004; revised manuscript received August 8, 2004,
ccepted September 13, 2004.nvestigated the relationship between plasma levels of BNP
nd hemodynamic parameters of LV contractile perfor-
ance in symptomatic patients with pressure overload
ardiomyopathy due to aortic valve stenosis and normal LV
ystolic function.
ETHODS
atients. Between January and November 2003, 40 con-
ecutive symptomatic patients with aortic valve stenosis (age
0  1 years , range 27 to 81 years) with a peak aortic valve
elocity of 2.5 m/s referred for elective diagnostic left-
ight heart catheterization were included. All patients pre-
ented either with heart failure, angina, and/or exertional
resyncope or syncope due to AS. Patients with primary
ardiomyopathy, ischemic cardiomyopathy, atrial fibrilla-
ion, or renal insufficiency defined by a serum plasma
reatinine level 0.16 mmol/l were excluded. At time of
nvestigation, 10 patients were treated with digoxin and 13
atients received angiotensin-converting enzyme inhibitors
nd diuretics. No patient was taking beta-blockers at the
ime of the study. Because of ethical considerations, medical
herapy remained unchanged at the time of study. Clinical
ostoperative in-hospital follow-up was obtained in all
atients. Ten age- and gender-matched subjects free of
ngina, heart failure, renal failure, or other cardiorenal
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thical committee.
eft-right heart catheterization. Catheterization of the
eft and right sides of the heart was performed from the
ight femoral artery and vein. Pulmonary capillary wedge
ressure (PCWP) was measured by use of a Swan-Ganz
atheter (Baxter Edwards, Deerfield, Illinois), whereas LV
ressure was recorded with a catheter positioned in the LV
avity. Left ventricular angiograms were obtained in the
ight anterior oblique coronary artery and left anterior
blique coronary artery positions. Left ventricular volumes
nd ejection fractions were derived from the single-plane
ngiogram using the area-length method. An impaired
reload reserve was defined by the presence of LV end-
iastolic pressure 16 mm Hg (12), whereas afterload
ismatch was assessed by the ratio of systolic wall stress
ver ejection fraction (13,14).
oppler echocardiography. Echo-Doppler study was per-
ormed immediately before cardiac catheterization accord-
ng to the guidelines of the American Society of Echocar-
iography (15). The pressure gradient across the aortic valve
as estimated from peak flow velocity detected by
ontinuous-wave Doppler echocardiography with the sim-
lified Bernouilli equation. The mean aortic valve gradient
as obtained by tracing the continuous-wave flow velocity
ignal across the aortic valve. The aortic valve area was
alculated using the continuity equation (16). Left ventric-
lar end-diastolic and end-systolic meridional wall stress
WS) were calculated from M-mode data in combination
ith pressure data, using the following formula: WS 
.334  P  LVID/(PWT  [1  PWT/LVID]), where
 LV pressure, LVID LV internal diameter, and PWT
posterior wall thickness. End-systolic wall stress was
alculated using systolic LV pressure, PWT, and LVID at
nd-systole, whereas end-diastolic wall stress was calculated
sing LV pressure, PWT, and LVID at end-diastole
17,18). Left ventricular mass was calculated by the equation
f Devereux et al. (19): LV mass  1.04 ([LVDD  IVSD
PWD]3  LVDD3)  14 and normalized to body
urface area (LVMI), where LVDD  LV end-diastolic
iameter, IVSD  interventricular thickness at end-
iastole, and PWD  posterior wall thickness at end-
iastole. Measurements were done by two experienced
bservers unaware of the clinical data.
easurement of BNP plasma levels. Before diagnostic
atheterization, when the patient was in a stable hemody-
amic condition, 5 ml of whole blood was drawn from the
Abbreviations and Acronyms
AS  aortic stenosis
BNP  B-type natriuretic peptide
LV  left ventricle/ventricular
PCWP  pulmonary capillary wedge pressureemoral vein for subsequent BNP measurements. B-type ratriuretic peptide was measured using the rapid, point-of-
are Triage B-type Natriuretic Peptide test (Biosite Diag-
ostics Inc., San Diego, California). As previously de-
cribed, the Triage BNP test is a fluorescence immunoassay
or the quantitative determination of BNP in whole blood
r plasma specimens. The measurable range of the Triage
NP test is from 5 to 1,300 pg/ml with a within-assay
oefficient of variation of 5.2%. Using this system, BNP
evels in controls ranged from 22 to 92 pg/ml (mean 62 
2 pg/ml).
tatistical analysis. All results are given as mean values 
EM. Comparisons between groups for continuous vari-
bles were made using t tests or one-way analysis of variance
here appropriate. Pearson’s correlation coefficient was used
o assess the association between BNP levels and hemody-
amic variables. Because the distribution of the BNP levels
as positively skewed, the natural log transformation was
sed, and all analyses used log-transformed values unless
therwise specified. Statistical significance was set at a
wo-tailed probability level of 0.05.
ESULTS
linical characteristics and plasma levels of BNP. Table
summarizes baseline hemodynamic and clinical character-
stics of patients with AS. Aortic valve area ranged from
.20 to 1.20 cm2, mean 0.69  0.05 cm2, whereas the mean
radient across the aortic valve was 59  4 mm Hg. The
ause of the AS was degenerative calcification in 38 patients
nd rheumatic in 2 patients.
Patients with AS were divided into two groups: group
consisted of 20 patients with normal preload reserve
haracterized by LV end-diastolic pressure 16 mm Hg;
roup B consisted of 20 patients with impaired preload
able 1. Characteristics of Patients With Aortic Valve Stenosis
Mean Value (Range)
ge (yrs) 70  1
ender (M/F) 17/23
V EF (%) 72  4
CWP (mm Hg) 13  1
VEDP (mm Hg) 18  1
VEDVI (ml/m2) 71  4
ean gradient (mm Hg) 59  4
VA (cm2) 0.69  0.05
nd-systolic wall stress (kdynes/cm2) 127  9
nd-diastolic wall stress (kdynes/cm2) 32  3
V mass index (g/m2) 111  7
NP (pg/ml) 232 37
ime to surgery (days) 23  8
ostoperative hospital stay (days) 12  1
linical deterioration (n) 17
Left-sided heart failure (n) 8
Right-sided heart failure (n) 8
Hypotension (n) 1
VA  aortic valve area; BNP  B-type natriuretic peptide; EF  ejection fraction;
V  left ventricular; LVEDP  left ventricular end-diastolic pressure; LVEDVI 
ndexed left ventricular end-diastolic volume; PCWP  pulmonary capillary wedge
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n Table 2. As expected, AS patients with impaired
reload reserve were characterized by lower ejection
raction and fractional shortening and higher end-
iastolic and end-systolic wall stress, PCWP, and in-
exed LV end-diastolic volume as well as by a more
evere degree of afterload mismatch assessed by the ratio
f end-systolic WS over ejection fraction. No differences
n age, aortic valve area, mean transvalvular aortic pres-
ure gradient, or LV mass index were noted between
roups.
In the entire study population, BNP levels ranged from 7
o 934 pg/ml, mean 201 31 pg/ml. As shown in Figure 1,
lasma BNP levels were significantly higher in patients with
S compared with patients without AS. Of note, despite
imilar aortic valve area and LV mass index, AS patients
ith impaired preload reserve had significantly higher BNP
evels compared with AS patients with normal preload
eserve (Table 2, Fig. 1).
able 2. BNP and Hemodynamic Parameters in AS Patients











NP (pg/ml) 168  44 297 56 0.017
V EF (%) 79  3 64  7 0.044
S (%) 44  3 35  3 0.023
VEDVI (ml/m2) 60  3 82  6 0.003
CWP (mm Hg) 10  1 15  2 0.047
nd-systolic wall stress/EF
(kdynes/% cm2)
1.4  0.2 3.4 0.9 0.001
nd-systolic wall stress
(kdynes/cm2)
104  10 149 12 0.009
nd-diastolic wall stress
(kdynes/cm2)
19  2 44  11 0.001
VA (cm2) 0.68  0.05 0.70 0.04 NS
ean gradient (mm Hg) 58  5 59  4 NS
V mass index (g/m2) 100  7 121 11 NS
ge (yrs) 73  2 69  2 NS
S  aortic stenosis; FS  fractional shortening; other abbreviations as in Table 1.
igure 1. Serum B-type natriuretic peptide (BNP) levels in age-matched
ontrols (NI), aortic stenosis patients with normal (group A) and with
mpaired preload reserve (group B).elationship between plasma levels of BNP and hemo-
ynamics. In the entire study population, a positive rela-
ionship was noted between BNP and PCWP (r  0.558; p
0.001) and an inverse correlation was noted between
NP and fractional shortening (r  0.525; p  0.001),
nd aortic valve area (r0.449; p 0.006) (Fig. 2). Note
hat plasma BNP was also directly related to the extent of
ardiac hypertrophy as assessed from the LV mass index
Fig. 2). Furthermore, a significant positive relationship was
oted between BNP and markers of diastolic wall stress
Fig. 3), such as LV end-diastolic wall stress (r  0.437; p
igure 2. Correlations between log-transformed (Ln) B-type natriuretic
eptide (BNP) and parameters of contractile function. FS  fractional
hortening; LV  left ventricular; PCWP  pulmonary capillary wedge
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sovolumic relaxation time (r  0.412; p  0.02).
n-hospital course and clinical follow-up. All patients
nderwent aortic valve replacement 23  8 days after
iagnostic heart catheterization (Table 3). No patient died
mmediately or late after aortic valve replacement. Seven-
een patients experienced clinical deterioration, with symp-
oms of left-sided heart failure in eight patients, right-sided
eart failure in eight patients, and hypotension in one
atient. Patients with clinical deterioration were character-
zed by significantly higher baseline preoperative BNP
evels, end-diastolic wall stress, PCWP, and length of
igure 3. Correlations between log-transformed (Ln) B-type natriuretic
eptide (BNP) and parameters of diastolic load. IVRT  isovolumic
elaxation time; LVEDVI  indexed left ventricular end-diastolic volume.ospital stay, as compared with those without clinical events. Ejection fraction, fractional shortening, aortic valve
rea, systolic wall stress, and mean gradient were similar in
oth groups (Table 3).
ISCUSSION
he present study investigated the relationship between circu-
ating BNP levels and hemodynamic indexes of diastolic and
ystolic load in a pressure overload heart failure model. The
esults can be summarized as follows: 1) BNP levels are
levated in patients with pressure overload cardiomyopathy
rrespective of the presence of overt LV systolic dysfunction; 2)
lasma BNP levels are related to both diastolic and systolic
ndexes of hemodynamic load; 3) plasma BNP levels were
igher in AS patients with elevated filling pressures despite
elatively preserved LV ejection fraction; and 4) patients with
linical deterioration postoperatively were characterized by
ignificantly higher baseline BNP levels.
NP and heart failure. B-type natriuretic peptide is a
ardiac-specific peptide whose synthesis appears to correlate
ell with circulating BNP levels (20). The detection of BNP
as emerged recently as a highly sensitive and accurate method
or the detection of LV systolic (21) and diastolic dysfunction
22). In addition, elevated levels of BNP have been reported in
S (11,23,24), during ischemia (25,26), and in hyper-
rophic cardiomyopathy (27). The present study corroborates
hese data by finding elevated levels of BNP in patients
ith symptomatic aortic valve stenosis. Nevertheless, in the
resent study, even those without overt LV systolic dysfunction
ad significantly higher BNP levels compared with the nor-
als. Similar observations were reported by Talwar et al. (28)
ho described elevated levels of N-terminal BNP and
ardiotrophin-1 in AS patients without major wall motion
bnormalities on echocardiography.
egulation of BNP production. A variety of mechanisms
ight be responsible for this BNP generation. First,
able 3. Preoperative BNP and Hemodynamic Parameters in










NP (pg/ml) 399 82 124  41 0.011
ime to surgery (days) 25  5 24  6 NS
ength of hospital stay
(days)
14  1 9  1 0.003
V EF (%) 65  7 75  3 NS
VEDVI (ml/m2) 76  7 64  4 NS
CWP (mm Hg) 15  2 10  1 0.027
nd-systolic wall stress
(kdynes/cm2)
130  16 117  9 NS
nd-diastolic wall stress
(kdynes/cm2)
37  4 24  3 0.038
VA (cm2) 0.54  0.04 0.62  0.04 NS
ean gradient (mm Hg) 62  8 66  4 NS
V mass index (g/m2) 118  11 104  9 NS
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tudy population, ischemia seems unlikely because no
atient had a transient increase in troponin levels or
ardiac enzyme markers at the time of the exam, and
atients with overt coronary artery disease were excluded.
econd, mRNA of BNP is considered as a molecular
arker of LV hypertrophy (9). Consistent with these
xperimental postulates and with previous clinical and
xperimental studies (32,33), plasma BNP levels were
irectly related to LV mass in our cohort of patients with
S, suggesting that BNP levels may reflect the extent of
ypertrophic growth. Finally, several studies have dem-
nstrated that alterations in the LV wall stress are
undamental in regulating cardiac plasticity. Previous
tudies in patients with AS indicated that LV systolic
oad may be related to BNP production. In our study,
NP was, indeed, related inversely to fractional shorten-
ng and appeared to be proportional also to the degree of
S severity. However, in contrast with the study by Ikeda
t al. (11), no relation between BNP levels and systolic
all stress was observed. This could be related to the
atient selection because our study included mostly
atients with preserved LV systolic function. Alterna-
ively, elevated LV diastolic wall stress has previously
een shown to promote myocardial gene expression and
roduction of neurohormones (34), cytokines (35), stress
roteins (36), and growth factors. Similar to up-
egulation of transcription factors such as early growth
esponse factor-1 and cellular myelocytomatosis onco-
ene (37), BNP appears to be an early responsive gene
2,10) that is up-regulated at the early stage of pressure
verload, well before the development of LV hypertrophy
38,39). Therefore, it is attractive to hypothesize that
NP is regulated primarily by changes in wall stress and
hat its up-regulation is one of the early steps in the
nduction cascade of cardiac growth. Corroborating this
ypothesis, Langenickel et al. (40) demonstrated in a
acing dog heart failure model that cardiac BNP mes-
enger ribonucleic acid expression will only selectively be
p-regulated in overt heart failure when ventricular
tretch is high. This is in apparent contrast with ventric-
lar atrial natriuretic peptide expression that is up-
egulated in congestive LV dysfunction, regardless of the
oading conditions (40). In addition, in an isolated
apillary muscle preparation, continuous diastolic over-
tretch induces BNP gene expression and release (9). Our
linical data corroborate these experimental observations
y demonstrating a significant relationship between end-
iastolic wall stress and BNP generation. Taken together,
ur data strongly suggest that, in human pressure over-
oad hypertrophy, regulation of BNP expression and
roduction is complex, and, besides a possible role of
ncreased cardiac mass or systolic load, diastolic stretch
oad is likely to be the key mechanical stimulus triggering
n-and-off BNP expression and production.linical implications and conclusions. Our data indicate
hat BNP may be an excellent screening tool for LV
iastolic dysfunction in patients with pressure overload
ardiomyopathy and normal LV systolic function. We
oticed a broad range of BNP levels even in patients with
pparently normal LV ejection fractions. However,
henever hypertrophy is inadequate to return systolic
all stress to normal levels, afterload mismatch will occur
nd will trigger transition from compensated hypertrophy
o failure with preload impairment. In our study, these
atients were characterized by higher BNP levels. These
levated BNP levels could not be purely explained by
arked LV hypertrophy. In contrast, elevated BNP levels
ncreased in parallel with increases in end-diastolic wall
tress, LV dilation, and filling pressures. On one hand,
his has pathophysiologic implications corroborating that
verstretch and LV dilation are important mechanical
actors responsible for the induction and subsequent
ecretion of BNP. On the other hand, it may have clinical
mplications, because plasma BNP appears to predict the
ctual hemodynamic state of an individual patient and
eflects noninvasively the transition from compensated to
ecompensated heart failure. Thus, BNP assessment may
epresent an important adjunct for the early and adequate
ecognition of LV dysfunction in this patient cohort. It is
lso of note that patients with higher in-hospital mor-
idity after valve replacement had elevated preoperative
NP as compared with patients with an uncomplicated
ostoperative course. This suggests that preoperative
NP assessment may also bear prognostic information
nd identify a high-risk subgroup of AS patients with
orse outcome after aortic valve replacement. Neverthe-
ess, the design of the study did not allow us to address
he value of BNP for clinical decision-making in patients
ith asymptomatic moderate or severe AS. Prospective
ollow-up studies are needed to further elucidate these
ssues.
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